Stocksigma LogoStocksigma Logo

Eris Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)

■ Revenue: 892 (+12.6% YoY | +2.2% QoQ) ■ EBITDA: 309 (+7.3% YoY | +4.4% QoQ) ■ EBITDA Margin (%): 34.7 (-171 bps YoY | +74 bps QoQ) ■ PAT: 184 (+52.9% YoY

Eris Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)

Eris Lifesciences Ltd · Outcome · 26 Oct 2026, 7:19 pm

Eris Lifesciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 892 (+12.6% YoY | +2.2% QoQ) ■ EBITDA: 309 (+7.3% YoY | +4.4% QoQ) ■ EBITDA Margin (%): 34.7 (-171 bps YoY | +74 bps QoQ) ■ PAT: 184 (+52.9% YoY | +29.1% QoQ) ■ EPS (INR): 13.3 (+50.4% YoY | +29.1% QoQ)

Original exchange filing (PDF)

More announcements from Eris Lifesciences Ltd

All Eris Lifesciences Ltd announcements